A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Voxtalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 17 Apr 2017 Results published in the Investigational New Drugs
- 26 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.